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Chronic obstructive pulmonary disease and emphysema are a frequent result of long-term
smoking, but the exact mechanisms, specifically which types of cells are associated with the
lung destruction, are unclear.
Methods and Findings
We studied different subsets of lymphocytes taken from portions of human lungs removed
surgically to find out which lymphocytes were the most frequent, which cell-surface markers
these lymphocytes expressed, and whether the lymphocytes secreted any specific factors that
could be associated with disease. We found that loss of lung function in patients with chronic
obstructive pulmonary disease and emphysema was associated with a high percentage of
CD4
þ and CD8
þ T lymphocytes that expressed chemokine receptors CCR5 and CXCR3 (both
markers of T helper 1 cells), but not CCR3 or CCR4 (markers of T helper 2 cells). Lung
lymphocytes in patients with chronic obstructive pulmonary disease and emphysema secrete
more interferon gamma—often associated with T helper 1 cells—and interferon-inducible
protein 10 and monokine induced by interferon, both of which bind to CXCR3 and are involved
in attracting T helper 1 cells. In response to interferon-inducible protein 10 and monokine
induced by interferon, but not interferon gamma, lung macrophages secreted macrophage
metalloelastase (matrix metalloproteinase-12), a potent elastin-degrading enzyme that causes
tissue destruction and which has been linked to emphysema.
Conclusions
These data suggest that Th1 lymphoctytes in the lungs of people with smoking-related
damage drive progression of emphysema through CXCR3 ligands, interferon-inducible protein
10, and monokine induced by interferon.
Introduction
Chronic inhalation of tobacco smoke causes progressive lung destruction in susceptible
individuals, resulting in chronic obstructive pulmonary disease (COPD) and emphysema, two
well-described clinical syndromes with poorly understood pathogenesis [1,2,3]. A role for T
helper cells in the pathogenesis of obstructive lung disease has been established with asthma,
where T helper 2 (Th2) cells are strongly linked to both human and experimental disease
[4,5,6,7]. A potential role for T cells in COPD has also been suggested in several recent studies
that show CD8
þ T cells are increased in the lungs of people who smoke [8,9,10,11]. T cells cause
tissue injury through their secreted products such as cytokines; in mice, overexpression of
interleukin (IL)-13, a T cell cytokine that is strongly implicated in the pathogenesis of
experimental asthma, resulted in increased production of proteases and enlargement of
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limitation, another characteristic of human asthma, is
clinically linked to an accelerated rate of loss of lung function
in smoker individuals [13]. It has been suggested, therefore,
that asthma and COPD may involve the same type of
recruited inﬂammatory cells, differing only in their location
within the lung [14].
Chemokines, their receptors, and cell adhesion molecules
regulate migration of immune cells into inﬂamed tissue
[15,16,17,18]. T helper 1 (Th1) cells have been shown to
secrete interleukin 2 and interferon gamma (IFN-c), and
express a distinct repertoire of chemokine receptors such as
CCR5 and CXCR3 [19,20,21]. In contrast, Th2 cells that are
biased to produce IL-4 and IL-5 express mainly CCR4 and
CCR3 [22,23,24,25]. Immunoﬂuorescent analysis of airway
mucosal biopsies in patients with asthma showed that most T
cells co-express IL-4 and CCR4, but, in contrast, T cells in
airways of patients with COPD and pulmonary sarcoidosis
produce IFN-c and express high levels of CXCR3, while
lacking CCR4 expression [26]. In addition to T cells, a wide
variety of other inﬂammatory cells have been shown to
express distinct chemokine receptors that are critical for
their homing, suggesting a universal mechanism for regulat-
ing immune responses. Interferon-inducible protein 10 (IP-
10), monokine induced by interferon gamma (MIG), and
interferon-inducible T cell alpha chemoattractant (I-TAC)
are three known ligands for CXCR3 produced by normal and
injured epithelial cells and T cells that are required for
homing of Th1 cells [27,28,29]. In addition to regulation of
chemotaxis and homing, other functions have been ascribed
to chemokines, including modulation of T cell fate by direct
effects on differentiating T cells, and regulation of proteolysis
in blood monocytes [19,30].
In this study we determined the dominant T helper
phenotype in lung samples from ex-smoker individuals with
moderate to severe COPD and emphysema and control
individuals with no evidence of smoking-related lung disease.
Analysis of chemokine receptor expression on isolated
peripheral lung lymphocytes from ex-smokers with COPD/
emphysema indicated that both CD4 and CD8 T helper cells
are strongly polarized to the Th1 phenotype compared to T
cells isolated from lung tissue of normal individuals or
individuals with non-smoking-related obstructive lung dis-
ease. The same cells spontaneously secreted more IFN-c and
CXCR3 receptor ligands MIG and IP-10 in the COPD and
emphysema group than in the group without emphysema.
Further, IP-10 and MIG, but not IFN-c, upregulated macro-
phage metalloelastase (matrix metalloproteinase [MMP]-12)
from isolated lung macrophages. Together, our ﬁndings
reveal the strong association between COPD/emphysema-
and Th1-driven adaptive immunity, suggesting a link to lung
destruction mediated by IFN-c, MIG, and IP-10.
Methods
Participants
Twenty-eight non-atopic ex-smoker individuals (see Table
1) undergoing medically necessary lung resection were
serially entered into the study: ten individuals with no COPD
and no evidence of emphysema (control group) and eighteen
individuals (diseased group) with moderate to severe COPD
and evidence of emphysema as determined by pulmonary
function tests, high-resolution computed tomography (CT),
or conventional CT scan. All participants were ex-smokers
who had quit smoking for a mean (SD) of 7 (2) y and 4 (2) y in
COPD/emphysema and control groups, respectively. COPD
was diagnosed according to the criteria recommended by the
National Institutes of Health/World Health Organization
workshop summary [31]. Participants in the control and
COPD/emphysema groups had similar (mean [SD] of 54 [6]
and 45 [5], respectively) ‘‘pack-year’’ smoking histories, where
smoking one pack of cigarettes per day each year is deﬁned as
one pack-year.
All participants were recruited from the surgical clinic at
the Michael E. DeBakey Veterans Affairs Medical Center and
the Methodist Hospital, and were undergoing lung resection
for diagnostic or therapeutic purposes (Table 1). Study
protocols were approved by the institutional review board
for human studies, and informed consent was obtained from
all participants. Participants had no history of allergy or
asthma and had not received oral/systemic corticosteroids
during the last 6 mo. At the time of study, all participants had
been free of acute symptoms suggestive of upper or lower
respiratory tract infection for the 6 wk preceding the study.
Table 1. Clinical and Demographic Characteristics of Participants
Emphysema (n=18) No Emphysema Control (n=10) p-Value
a
LVRS (n) 8
Small peripheral cancer (n) 10 5
Benign lesion
b (n) 5
Age (mean 6 SE) 68 6 26 5 6 5 0.60
Percent FEV1 (mean 6 SE) 45 6 49 1 6 3 ,0.001
Pack-years smoking (mean 6 SE) 54 6 64 5 6 5 0.45
QT (mean 6 SE) 7 6 24 6 2 0.54
a p-Values are for the comparison of emphysema with control participants (Student’s T test).
b Histological diagnoses included lipoma, papiloma, and benign scar.
LVRS, lung volume reduction surgery; SE, Standard Error; percent FEV1 l/s, percent predicted FEV1 in liters/second; QT, the number of years since the individuals had stopped
smoking.
DOI: 10.1371/journal.pmed.0010008.t001
PLoS Medicine | http://www.plosmedicine.org October 2004 | Volume 1 | Issue 1 | e8 076
Th1 Immune Cells in Human EmphysemaCT-Based Evaluation for Emphysema
High-resolution CT (two in emphysema group and two in
control group) or conventional CT analysis was used to detect
emphysema, characterized by the presence of areas of low
attenuation contrasted with surrounding normal lung paren-
chyma [32,33]. CT scans were used by a radiologist to separate
participants on the basis of the presence or the absence of
any objective evidence for centrilobular, panacinar, or
paraseptal emphysema with a detection limit of greater than
3-mm low attenuation density [34].
Isolation of Lung Lymphocytes
Lung lymphocytes were isolated by modifying established
protocols, using a combination of mechanical fragmentation,
enzyme digestion, and centrifugation procedures described
previously [35,36,37]. Viable lymphocytes were separated
from whole lung inﬂammatory cells (macrophages, eosino-
phils, and neutrophils) using an immunomagnetic positive
separation technique (autoMACS, Miltenyi Biotec, Auburn,
California, United States). Brieﬂy, lung leukocytes were
labeled with paramagnetic bead-conjugated anti-CD3,
-CD19, and -CD56 to positively select T, B, and NK cells,
according to the manufacturer’s instructions. Each of the
harvested cell populations was used directly for in vitro assays
or was cryopreserved in aliquots of 1 3 10
7 cells for future
analysis.
Antibodies
The following monoclonal antibodies were purchased from
BD Biosciences Pharmingen (San Diego, California, United
States): FITC-, Cy5-, and PE-conjugated anti-CD4, -CD8,
-CD3, -CD14, -CD69, -CXCR3, -CCR3, -CCR4, and -CCR5.
For enzyme-linked immunosorbent assay studies, anti-human
antibodies to IFN-c, IL-4, IP-10, MIG, I-TAC, and the
appropriate secondary reagents were purchased from R&D
Systems (Minneapolis, Minnesota, United States).
Quantification of Polarized Peripheral Blood and Lung
Lymphocyte Subsets
Phenotypic characterization of T cells was done by two-
color ﬂow cytometry (Epic XL FL, Beckman Coulter,
Allendale, New Jersey, United States) using combinations of
the following monclonal antibodies: FITC-conjugated anti-
CD4, -CD8, and -CD14; PE- and Cy5-conjugated anti-CCR4,
-CCR3, -CCR5, and -CXCR3. Freshly isolated lung lympho-
cytes were resuspended to 1 3 10
7 cells/ml, and 50 ll of cells
was incubated with antibodies to CD3 and CD4 or CD8.
Intracytoplasmic Cytokine Staining
Lung lymphocytes were cultured in the presence or
absence of phorbol myristate acetate (PMA)/ionomycin and
brefeldin A for 12 h. Cells were harvested, ﬁxed with
formaldehyde, permeabilized with saponin, and intracellu-
larly labeled for IFN-c and IL-4, in addition to staining for
surface CD69, CD4, and CD8 according to the manufacturer’s
recommendations (Fastimmune, BD Biosciences Pharmin-
gen).
In Vitro T Cell Culture and Cytokine Assay
Lung lymphocytes were isolated from surgical tissue and
cultured in vitro in triplicate for 4 d. Supernatants were
collected and stored at –80 8C for future analysis. Standard
antibody-based enzyme-linked immunosorbent assay was
used to measure supernatant concentrations of IP-10, MIG,
IL-4, and IFN-c according to the manufacturer’s instructions
(R&D Systems and BD Biosciences Pharmingen).
Detection of MMP12 by Western Blotting, and Real-Time
PCR
Peripheral blood mononuclear cells and lung macrophages
were isolated by positive selection using immunomagnetic
beads conjugated with anti-CD14, and cultured in serum-free
medium (RPMI, L-glutamine, and Pen/Strep) prior to over-
night stimulation with 0, 50, 250, or 500 ng/ml of IFN-c, IL-4,
MIG, I-TAC, and IP-10. Supernatants were collected, and
MMP12 was detected using anti-human MMP12 (R&D
Systems) by Western blotting according to the manufacturer’s
instructions.
Total cellular RNA was extracted from CD14
þ lung
macrophages stimulated overnight with rIP-10 (500 ng/ml)
in the presence or absence of blocking anti-CXCR3 anti-
bodies (5 lg/ml, R&D Systems). Two-step real-time reverse
transcription PCR was used to determine the relative
expression of mRNA using the ABI Perkin Elmer Prism
5700 Sequence Detection System (Applied Biosystems, Foster
City, California, United States) as described previously [38].
Immunostaining and Histopathology
Parafﬁn-embedded, and fresh-frozen lung sections (5 lm)
were immunostained using monoclonal antibodies against
human MMP12 (R&D Systems) or non-immune antisera by an
immunoperoxidase protocol (Vectastain Elite, Vector Labs,
Burlingame, California, United States) and counterstained
with hematoxylin as recommended by the manufacturer.
Statistical Analysis
The Mann-Whitney test (non-parametric, two-tailed) and
Student’s T test (two-tailed) were used to compare differences
between the two groups of subjects. p , 0.05 was considered
statistically signiﬁcant.
Results
Th1 Immune Bias of Peripheral Lung Lymphocytes in
Emphysema
Inﬂammatory chemokines, cytokines, and their receptors
are upregulated at sites of inﬂammation and play a key role in
the recruitment of leukocytes to peripheral tissues in
response to injury [17,39]. To detect Th1 polarization, we
assessed lung lymphocytes for expression of CCR5 (a receptor
for several Th1 chemokines) and CXCR3 (the receptor for IP-
10, I-TAC, and MIG). We screened for the presence of Th2
cells by assessing T cell expression of CCR4—a receptor for
eotaxin/CCL11, macrophage chemoattractant protein 3
(CCL7), and thymus- and activation-regulated chemokine
(CCL17) [40,41]—and CCR3, a receptor for eotaxin and
related chemokines. Flow cytometry revealed very low
expression of CCR3 and CCR4 (1%–3%) in control (n=
10) and emphysema (n=18) groups, and did not discriminate
between these populations (Figure 1A and 1B; data not
shown). These ﬁndings were in sharp contrast to the
enhanced expression of both CCR5 and CXCR3, as shown
in representative histograms (Figure 1A). These Th1-speciﬁc
chemokine receptors were expressed prominently on lung
lymphocytes from all participants, but their expression was
signiﬁcantly enhanced in the setting of emphysema (Figure
PLoS Medicine | http://www.plosmedicine.org October 2004 | Volume 1 | Issue 1 | e8 077
Th1 Immune Cells in Human Emphysema1A–1C). Further, both CD4 and CD8 T cells expressed CCR5
at the same level (Figure 1C). In contrast, we found highly
variable expression (0.5%–30%) of CCR4, CXCR3, and CCR5
on peripheral blood lymphocytes isolated from the same
participants, and this variation did not correlate with the
presence of disease in either group (data not shown).
Furthermore, we compared the lung lymphocyte CCR5 and
CXCR3 proﬁles among the eight participants with emphyse-
ma alone (lung volume reduction surgery for emphysema;
non-cancer) and ten participants with emphysema and
accompanying cancer (lung resection for treatment of small
peripheral cancer), and found that these two groups cannot
be distinguished based on these indices (Figure 1D; data not
shown).
Although human lung macrophages are not known to
express CXCR3, we suspected based on the immunohisto-
chemical localization of this chemokine receptor that CD14
þ
cells in the lungs of ex-smoker individuals with emphysema
accounted for much of the total lung CXCR3
þ immuno-
reactivity (Figure 2A; data not shown). To conﬁrm this, we
determined the percent of total lung cells expressing CD14
and CD11b—which are both markers of monocytes/macro-
phages—and CXCR3. We found that over 40% of CD14
þ cells
from participants with emphysema but not control partic-
ipants were also positive for CXCR3 (Figure 2). In addition,
there was a signiﬁcant negative association between CXCR3
expression on lung T cells and the percent of predicted
forced expiratory volume in 1 s (FEV1), based on an R
2
Figure 1. Chemokine Receptor Expression on Peripheral Lung Lymphocytes
(A) Single color histograms showing expression of chemokine receptors CCR4, CCR5, and CXCR3 from representative control and emphysema
participants.
(B) Pooled data from all participants (control, n=10; emphysema, n=18) showing percent (median 6 SD) of total lung lymphocytes expressing
CCR4 and CCR5.
(C) Pooled data from same participants showing percent (median 6 SD) CCR5 expression on CD4 (top) and CD8 (middle) T cells, and CXCR3
expression on unfractionated T cells (bottom) from the same participant groups.
(D) Analysis of total lung lymphocyte chemokine receptor (median 6 SD) proﬁles among participants with emphysema. Participants had either
(1) lung volume reduction surgery for emphysema (non-cancer, n=8) or (2) lung resection for treatment of small peripheral cancer (n=10).
Participants showed similar inﬂammatory indices as determined by CCR5 expression.
In (B) and (C), *, p , 0.001; , p=0.01; z, p=0.02;
R
, p=0.007 (Mann-Whitney test) for the comparison of emphysema and control groups.
DOI: 10.1371/journal.pmed.0010008.g001
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Th1 Immune Cells in Human Emphysemagoodness-of-ﬁt statistic of 0.27 (Figure 2C; p = 0.0089, r =
 0.52). Together, these data indicate that a strong type 1 bias
is characteristic of the T cells isolated from the peripheral
lung of participants with COPD and emphysema and that this
immune phenotype correlates with the lung destruction that
is characteristic of this disease. Further, we have shown for
the ﬁrst time, to our knowledge, that CXCR3 expression, a
marker of Th1 inﬂammation, extends to lung monocytes and
macrophages.
IFN-c, IP-10, and MIG But Not IL-4 Are Expressed by Lung
Lymphocytes
We sought additional functional data to conﬁrm the
apparent Th1 bias of peripheral lung inﬂammatory cells
isolated from ex-smoker individuals. Freshly isolated lung
lymphocytes that were not otherwise manipulated secreted
high levels of IFN-c, MIG, and IP-10, with signiﬁcantly greater
secretion of both cytokines from lymphocytes of participants
with emphysema (Figure 3A–3C). Interestingly, we could not
detect appreciable amounts of I-TAC, another known ligand
for CXCR3, in lung lymphocytes of control participants or
those with emphysema (data not shown). Similar results were
obtained using intracytoplasmic cytokine staining of the same
cells (Figure 3D), in which PMA/ionomycin stimulation
strongly induced IFN-c production from CD69
þ/CD8
þ lung
lymphocytes. Surface staining for CD4 was not feasible with
this protocol; however, the percentage of CD8
 /IFN-c
þ cells
was approximately equal to that of CD8
þ/IFN-c
þcells (median
[SD], 19[6] versus 16[4], respectively). Because total numbers
of CD4
þand CD8
þT cells were approximately equivalent, this
suggests that non-CD8
þ/IFN-c
þ cells are largely CD4
þ, and
therefore Th1 cells. Finally, the typical Th2 cytokine, IL-4, was
not detected in either group, as determined by enzyme-linked
immunosorbent assay or intracytoplasmic cytokine staining
(Figure 3E; data not shown), conﬁrming the marked Th1 bias
of the immune response that underlies smoking-related lung
inﬂammation and emphysema.
IP-10 and MIG But Not IFN-c Directly Upregulate MMP12
through CXCR3
Emphysema and irreversible airway limitation that is
characteristic of chronic tobacco smoking are related to the
destruction of elastin and the resulting loss of lung elastic
recoil. Therefore, to be relevant to the pathogenesis of airway
obstruction, type 1 inﬂammation must be shown to promote
lung elastolysis. Because loss of elastin is regulated by
proteinases [42], we next determined if expression of MMPs,
in particular the elastases MMP9 and MMP12, was regulated
by IP-10, MIG, and IFN-c, the principal cytokines detected in
emphysematous lung. Indeed, isolated peripheral lung mac-
rophages, but not isolated blood monocytes, secreted MMP12
in response to IP-10 and MIG, but not IFN-c (Figure 4A; data
not shown). These ﬁndings reﬂect a speciﬁc receptor–ligand
interaction because in the presence of a CXCR3 function-
Figure 2. Expression of CXCR3 in Lungs of Control and Emphysematous Smoker Individuals
(A) Representative forward and side-scatter characteristics of whole lung cells from a participant with COPD and emphysema. Anti-CD11b PE-
conjugated and anti-CD14 FITC-conjugated antibodies detect lung macrophages (middle), and histogram of mean ﬂuorescence intensity
showing anti-CXCR3-Cy5 and control antibodies (cIg) detects lung macrophages in the patient with emphysema.
(B) Pooled data from control individuals without (n=5) and with (n=8) emphysema. Columns are median, bars represent SD. *, p=0.009
(Mann-Whitney test) for the comparison of emphysema and control participants.
(C) Negative association between CXCR3 expression on CD3
þ T cells and FEV1 percentage predicted based on an R
2 goodness-of-ﬁt statistic of
0.27 (p=0.0089, r =  0.52, n=24).
DOI: 10.1371/journal.pmed.0010008.g002
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Th1 Immune Cells in Human Emphysemablocking antibody, IP-10 failed to induce MMP12 (Figure 4B).
Furthermore, immunohistochemical studies revealed that
lung macrophages of participants with emphysema, but not
control participants, speciﬁcally express MMP12 (Figure 4C
and 4D). Together, these ﬁndings indicate that Th1, but not
Th2, cytokines and related chemokines are required for
establishing the pro-elastolytic lung environment that under-
lies human emphysema.
Discussion
In this investigation, we characterized T cells and lung
macrophages isolated from emphysematous and non-emphy-
sematous human lungs. Three principal ﬁndings emerge from
our study. First, rather than being functionally diverse, as
suggested by the heterogeneous nature of humans, lung T
cells of ex-smoker individuals with emphysema are relatively
homogeneous and characterized by a marked Th1 bias.
Second, the principal Th1 chemokines, MIG and IP-10, are
linked to a pro-elastolytic lung environment because these
cytokines upregulate the elastase MMP12, which is associated
with emphysema. Finally, we found no signiﬁcant expression
of Th2 chemokine receptors, such as CCR3 and CCR4, or IL-4
production in lung lymphocytes. Together, our ﬁndings
demonstrate the role of the adaptive immune response in
COPD and suggest a primary role for Th1 cells in controlling
the main smoking-related physiologic and structural changes
of the lung.
Upregulation of CCR5 and CXCR3 on T cells and
accumulation of these cells in the lung periphery suggest
that aberrant, unremitting pulmonary recruitment of these
activated T cells is unique to people with smoking-related
lung disease, despite cessation of exposure to the inciting
agent, tobacco smoke. We showed that ex-smoker individuals
without obstructive lung disease or emphysema have com-
paratively little Th1-biased inﬂammation in their lungs; thus,
our ﬁndings reﬂect the inﬂammatory changes that are unique
to the COPD microenvironment. Additionally, lung lympho-
cytes isolated from four lifelong non-smoker individuals with
severe obstructive lung disease due to cystic ﬁbrosis or
bronchiolitis obliterans did not show a Th1 inﬂammatory bias
of the lung (S. Grumelli, F. Kheradmand, D. B. Corry,
unpublished data). This information conﬁrmed our ﬁnding
that the predominant Th1 bias in COPD/emphysema reﬂects
the microenvironment unique to the lungs of ex-smoker
individuals. The prevalence of asthma among people who
smoke is currently not known, but in order to study COPD/
emphysema in a population without other confounding
variables, people who might have had asthma were excluded,
Figure 3. IFN-c, MIG, and IP-10 Production by Isolated Lung Lymphocytes
(A–C) Lung lymphocytes from control individuals and participants with emphysema were cultured without additional stimulation for 3 or 4 d
and assessed for secretion of (A) IFN-c, (B) MIG, and (C) IP-10 (control, n=8; emphysema, n=12). Columns are median, bars represent SD.
*, p=0.007; , p=0.01; z, p=0.02 for the comparison of emphysema and control participants.
(D) The same cells from a representative ex-smoker individual with emphysema were either left unstimulated (No ST) or treated with PMA/
ionomycin (PMA/I) for 24 h and assessed for surface CD8 and CD69 expression and the intracytoplasmic accumulation of IFN-c by ﬂow
cytometry.
(E) Production of IL-4 by lung lymphocytes. Lung lymphocytes from a representative ex-smoker individual with emphysema were cultured for 24
h with or without PMA/ionomycin stimulation (PMA/I) and assessed for intracytoplasmic IL-4 and IFN-c accumulation by ﬂow cytometry.
DOI: 10.1371/journal.pmed.0010008.g003
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Th1 Immune Cells in Human Emphysemaand thus our ﬁndings are restricted to non-asthmatic
individuals with emphysema.
Our use of T cell chemokine receptor expression analysis
to determine recruitment of lung T cells is not without
precedent. Analysis by immunohistochemistry of airway
mucosa of people with atopic asthma after antigen challenge
revealed that large numbers of CCR4
þ and CCR8
þ T cells
express IL-4, and CCR4 expression was prominent in people
with severe atopic dermatitis, which decreased upon abate-
ment of disease activity [26,43]. Immunostaining of T cells in
synovial ﬂuid from individuals with rheumatoid arthritis
showed that virtually all of the T cells associated with
inﬂamed joints expressed CXCR3 and CCR5, representing
signiﬁcant enrichment compared to blood T cells from the
same participants. Furthermore, previous studies of smoker
individuals with COPD and normal lung function showed the
presence of CD8
þ/CXCR3
þ T cells in the airway epithelium
and submucosa [44]. We extend these ﬁndings by showing
CXCR3 expression on lung macrophages and CD4
þ T cells in
emphysema patients and the functional interplay between
Th1-related chemokines and elastolytic MMPs.
In addition to detailing surface chemokine receptor
expression, we have functionally conﬁrmed the marked Th1
bias of peripheral lung T cells, demonstrating that either at
rest or following stimulation, these cells secrete IFN-c and not
IL-4. Our ﬁndings therefore conﬁrm the utility of chemokine
receptor expression patterns in the initial assessment of T
cell effector phenotype.
Destruction of lung parenchyma in emphysema is thought
to occur through excessive proteolysis mediated by the
elastin-degrading enzymes MMP2, MMP9, and MMP12 from
the MMP family, and by neutrophil elastase from the serine
proteinase family [45,46]. Cytokines and chemokines are
substrates for MMPs, but they also regulate expression of
MMPs under pathological conditions [47,48]. We have shown
here that IP-10 and MIG, two chemokines that are secreted
from lung lymphocytes of participants with emphysema,
upregulate speciﬁcally MMP12 and thus favor a proteolytic
microenvironment that facilitates lung destruction. Strength-
ening the association between lung macrophages and IP-10/
MIG-dependent MMP12 secretion is the fact that we have
demonstrated that in humans macrophages, like T cells,
express CXCR3 and that this receptor is required for MMP12
secretion in response to IP-10/MIG stimulation. In addition to
deﬁning the predominant immune phenotype of emphysem-
atous lung, these additional ﬁndings implicate the principal
cell (macrophage), MMP (MMP12), and effector cytokines
(IFN-c, IP-10, and MIG) as likely underlying smoking-induced
lung destruction. We have further shown that these enzymes
may be regulated by proximal immune events driven by Th1
cells or Th1-associated cytokines. A question of major
importance for future study is, therefore, the nature of the
antigens and adjuvant factors that ultimately drive this
inﬂammatory response.
Although this was an entirely human study, our ﬁndings
show remarkable parallels with studies performed in mice.
MMP12 deﬁciency has been shown to protect mice against
emphysema after chronic exposure to cigarette smoke,
implying that MMP12 may be the key proteinase in the
development of emphysema in this species [49,50]. Studies
from both humans and mice therefore ﬁrmly suggest the
importance of MMP12 in the pathogenesis of emphysema.
Interestingly, in addition to solubilizing elastin, MMP12 is the
MMP most efﬁcient at degrading a1-antitrypsin, the primary
Figure 4. Regulation of MMP12 by Type 1 Cytokines
(A) CD14
þ, lymphocyte-depleted lung leukocytes were cultured with and without the indicated amounts of recombinant human IP-10 and IFN-c,
and supernatants were assessed for the presence of MMP12 by Western blotting.
(B) Fold increase relative to unstimulated of MMP12 mRNA from lung macrophages stimulated without (–) and with (þ) 500 ng/ml of IP-10 in the
presence or absence of a function-blocking antibody to CXCR3 as determined by real-time PCR.
(C and D) Lung tissue from a participant with emphysema (C) shows strong immune staining for MMP12 localized to macrophages (arrows), and
(D) shows lung tissue from a control participant without emphysema and with undetectable MMP12. The insets show a high-power view of lung
macrophages staining positive (C) and negative (D) for MMP12 (360) *, p=0.04.
DOI: 10.1371/journal.pmed.0010008.g004
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Thus, chemokine-induced upregulation of MMP12 may
orchestrate lung matrix degradation both directly and
indirectly through inactivation of a1-antitrypsin. The therapy
of COPD and emphysema is currently limited to pharmaco-
logic bronchodilation to relieve dyspnea, antibiotics for
intercurrent respiratory tract infection, and vaccination
against prominent respiratory pathogens. Aside from efforts
to prevent smoking or encourage cessation, there exist no
measures that prevent development of emphysema or treat
the speciﬁc causes of airway obstruction. By providing insight
into the immunopathogenesis of COPD, our ﬁndings provide
genuine hope that future therapies capable of preventing or
halting smoking-related lung disease may be possible.
Acknowledgments
We thank Dr. A. Clinton White for critical review of the manuscript,
Mr. Jeff Scott for technical assistance with ﬂow cytometry, Ms. Pamela
Smithwick, Ms. Rose Baglia, clinical research coordinator Dr Michael
Reardon, and all the individuals who generously participated in this
study. This work was supported by grants from the National Heart
Lung and Blood Institute (64061, 72419, 69585) and Baylor College of
Medicine (AI 36211). The funding provided by the National Hearth
Lung and Blood Institute made our study possible, but it had no
impact on any other matters such as study design, data collection and
analysis, decision to publish, or preparation of the manuscript. &
References
1. Barnes PJ (2001) Potential novel therapies for chronic obstructive
pulmonary disease. Novartis Found Symp 234: 255–267.
2. Senior RM (2000) Mechanisms of COPD: Conference summary. Chest 117:
320S–323S.
3. Hogg JC (2001) Chronic obstructive pulmonary disease: An overview of
pathology and pathogenesis. Novartis Found Symp 234: 4–19.
4. Corry DB, Grunig G, Hadeiba H, Kurup VP, Warnock ML, et al. (1998)
Requirements for allergen-induced airway hyperreactivity in T and B cell-
deﬁcient mice. Mol Med 4: 344–355.
5. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, et al. (1998)
Requirement for IL-13 independently of IL-4 in experimental asthma.
Science 282: 2261–2263.
6. Kay AB (1997) T cells as orchestrators of the asthmatic response. Ciba
Found Symp 206: 56–67.
7. Fahy JV, Corry DB, Boushey HA (2000) Airway inﬂammation and
remodeling in asthma. Curr Opin Pulm Med 6: 15–20.
8. Cosio MG, Guerassimov A (1999) Chronic obstructive pulmonary disease.
Inﬂammation of small airways and lung parenchyma. Am J Respir Crit Care
Med 160: S21–S25.
9. Di Stefano A, Capelli A, Lusuardi M, Caramori G, Balbo P, et al. 2001.
Decreased T lymphocyte inﬁltration in bronchial biopsies of subjects with
severe chronic obstructive pulmonary disease. Clin Exp Allergy 31: 893–
902.
10. Turato G, Zuin R, Saetta M (2001) Pathogenesis and pathology of COPD.
Respiration 68: 117–128.
11. Saetta M, Di Stefano A, Turato G, Facchini FM, Corbino L, et al. (1998)
CD8þ T-lymphocytes in peripheral airways of smokers with chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 157: 822–826.
12. Zheng T, Zhu Z, Wang Z, Homer RJ, Ma B, et al. (2000) Inducible targeting
of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-
dependent emphysema. J Clin Invest 106: 1081–1093.
13. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, et al. (1994)
Effects of smoking intervention and the use of an inhaled anticholinergic
bronchodilator on the rate of decline of FEV1. The Lung Health Study.
JAMA 272: 1497–1505.
14. He JQ, Connett JE, Anthonisen NR, Sandford AJ (2003) Polymorphisms in
the IL13, IL13RA1, and IL4RA genes and rate of decline in lung function in
smokers. Am J Respir Cell Mol Biol 28: 379–385.
15. Baggiolini M, Loetscher P (2000) Chemokines in inﬂammation and
immunity. Immunol Today 21: 418–420.
16. Sallusto F, Lanzavecchia A (2000) Understanding dendritic cell and T-
lymphocyte trafﬁc through the analysis of chemokine receptor expression.
Immunol Rev 177: 134–140.
17. Luster AD (2002) The role of chemokines in linking innate and adaptive
immunity. Curr Opin Immunol 14: 129–135.
18. Xie H, Lim YC, Luscinskas FW, Lichtman AH (1999) Acquisition of selectin
binding and peripheral homing properties by CD4(þ) and CD8(þ) T cells. J
Exp Med 189: 1765–1776.
19. Luther SA, Cyster JG (2001) Chemokines as regulators of T cell differ-
entiation. Nat Immunol 2: 102–107.
20. Kim CH, Rott L, Kunkel EJ, Genovese MC, Andrew DP, et al. (2001) Rules of
chemokine receptor association with T cell polarization in vivo. J Clin
Invest 108: 1331–1339.
21. Loetscher P, Uguccioni M, Bordoli L, Baggiolini M, Moser B, et al. (1998)
CCR5 is characteristic of Th1 lymphocytes. Nature 391: 344–345.
22. Muller KM, Jaunin F, Masouye I, Saurat JH, Hauser C (1993) Th2 cells
mediate IL-4-dependent local tissue inﬂammation. J Immunol 150: 5576–
5584.
23. Kamogawa Y, Minasi LE, Carding SR, Bottomly K, Flavell RA (1993) The
relationship of IL-4- and IFNg-producing T cells studied by lineage
ablation of IL-4-producing cells. Cell 75: 985–995.
24. Del Prete G (1992) Human Th1 and Th2 lymphocytes: Their role in the
pathophysiology of atopy. Allergy 47: 450–455.
25. D’Ambrosio D, Mariani M, Panina-Bordignon P, Sinigaglia F (2001)
Chemokines and their receptors guiding t lymphocyte recruitment in lung
inﬂammation. Am J Respir Crit Care Med 164: 1266–1275.
26. Panina-Bordignon P, Papi A, Mariani M, Di Lucia P, Casoni G, et al. (2001)
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of
allergen-challenged atopic asthmatics. J Clin Invest 107: 1357–1364.
27. Cole KE, Strick CA, Paradis TJ, Ogborne KT, Loetscher M, et al. (1998)
Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-
ELR CXC chemokine with potent activity on activated T cells through
selective high afﬁnity binding to CXCR3. J Exp Med 187: 2009–2021.
28. Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, et al. (2001)
The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are
natural antagonists for CCR3. J Biol Chem 276: 2986–2991.
29. Zlotnik A, Yoshie O (2000) Chemokines: A new classiﬁcation system and
their role in immunity. Immunity 12: 121–127.
30. Klier CM, Nelson EL, Cohen CD, Horuk R, Schlondorff D, et al. (2001)
Chemokine-induced secretion of gelatinase B in primary human mono-
cytes. Biol Chem 382: 1405–1410.
31. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global
strategy for the diagnosis, management, and prevention of chronic
obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic
Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit
Care Med 163: 1256–1276.
32. Uppaluri R, Mitsa T, Sonka M, Hoffman EA, McLennan G (1997)
Quantiﬁcation of pulmonary emphysema from lung computed tomography
images. Am J Respir Crit Care Med 156: 248–254.
33. Satoh K, Kobayashi T, Misao T, Hitani Y, Yamamoto Y, et al. (2001) CT
assessment of subtypes of pulmonary emphysema in smokers. Chest 120:
725–729.
34. Madani A, Keyzer C, Gevenois PA (2001) Quantitative computed
tomography assessment of lung structure and function in pulmonary
emphysema. Eur Respir J 18: 720–730.
35. Upham JW, McMenamin C, Schon HM, Robinson BW, Holt PG (1994)
Functional analysis of human bronchial mucosal T cells extracted with
interleukin-2. Am J Respir Crit Care Med 149: 1608–1613.
36. Goodacre R, Davidson R, Singal D, Bienenstock J (1979) Morphologic and
functional characteristics of human intestinal lymphoid cells isolated by a
mechanical technique. Gastroenterology 76: 300–308.
37. Fiocchi C (1985) Lymphoid cells of the gastrointestinal tract. Isolation
procedures. Acta Chir Scand Suppl 525: 11–23.
38. Corry DB, Rishi K, Kanellis J, Kiss A, Song Lz LZ, et al. (2002) Decreased
allergic lung inﬂammatory cell egression and increased susceptibility to
asphyxiation in MMP2-deﬁciency. Nat Immunol 3: 347–353.
39. Baggiolini M (2001) Chemokines in pathology and medicine. J Intern Med
250: 91–104.
40. Renauld JC (2001) New insights into the role of cytokines in asthma. J Clin
Pathol 54: 577–589.
41. Padrid PA, Cozzi P, Leff AR (1996) Cyclosporine A inhibits airway reactivity
and remodeling after chronic antigen challenge in cats. Am J Respir Crit
Care Med 154: 1812–1818.
42. Sternlicht MD, Werb Z (1999) ECM Proteinases. In: Kreis T, Vale RD,
editors. Guidebook to the extracellular matrix and adhesion proteins.
Oxford: Oxford University Press. pp. 503–562.
43. Wakugawa M, Nakamura K, Kakinuma T, Onai N, Matsushima K, et al.
(2001) CC chemokine receptor 4 expression on peripheral blood CD4þ T
cells reﬂects disease activity of atopic dermatitis. J Invest Dermatol 117:
188–196.
44. Saetta M, Mariani M, Panina-Bordignon P, Turato G, Buonsanti C, et al.
(2002) Increased expression of the chemokine receptor CXCR3 and its
ligand CXCL10 in peripheral airways of smokers with chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 165: 1404–1409.
45. Barnes PJ (2000) Chronic obstructive pulmonary disease. N Engl J Med 343:
269–280.
46. Cawston T, Carrere S, Catterall J, Duggleby R, Elliott S, et al. (2001) Matrix
metalloproteinases and TIMPs: Properties and implications for the treat-
ment of chronic obstructive pulmonary disease. Novartis Found Symp 234:
205–218.
47. Sternlicht MD, Werb Z (2001) How matrix metalloproteinases regulate cell
behavior. Annu Rev Cell Dev Biol 17: 463–516.
48. Kang T, Yi J, Guo A, Wang X, Overall CM, et al. (2001) Subcellular
PLoS Medicine | http://www.plosmedicine.org October 2004 | Volume 1 | Issue 1 | e8 082
Th1 Immune Cells in Human Emphysemadistribution and cytokine- and chemokine-regulated secretion of leukoly-
sin/MT6-MMP/MMP-25 in neutrophils. J Biol Chem 276: 21960–21968.
49. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD (1997) Requirement
for macrophage elastase for cigarette smoke-induced emphysema in mice.
Science 277: 2002–2004.
50. Churg A, Zay K, Shay S, Xie C, Shapiro SD, et al. (2002) Acute cigarette
smoke-induced connective tissue breakdown requires both neutrophils and
macrophage metalloelastase in mice. Am J Respir Cell Mol Biol 27: 368–374.
51. Gronski TJ Jr, Martin RL, Kobayashi DK, Walsh BC, Holman MC, et al.
(1997) Hydrolysis of a broad spectrum of extracellular matrix proteins by
human macrophage elastase. J Biol Chem 272: 12189–12194.
52. Liu Z, Zhou X, Shapiro SD, Shipley JM, Twining SS, et al. (2000) The serpin
alpha1-proteinase inhibitor is a critical substrate for gelatinase B/MMP-9 in
vivo. Cell 102: 647–655.
Patient Summary
Background. Many people develop long-term lung problems after
smoking, including a condition called emphysema. At the very end of the
airways are tiny air sacs. In healthy people, the air sacs stretch and relax
easily on breathing in and out. But in people with emphysema, the air
sacs fill up with air but can’t empty out properly, so air gets trapped,
making breathing difficult. While the symptoms of emphysema can be
treated, there are no treatments that can reverse the damage to the
lung.
What Did the Researchers Find? The researchers studied two groups of
patients, all ex-smokers who had been admitted to a hospital to have
part of their lung removed—some because of cancer, some for other
reasons. The researchers studied the lung samples and looked to see
exactly what type of immune cells the patients with emphysema had in
their lungs and found that most of the immune cells were of one
particular type. The researchers also showed that the immune cells could
tell other lung cells to produce chemicals that can damage the lung.
What Does This Mean for Patients? Lung damage in emphysema may
not be caused directly by toxins in cigarette smoke. Instead, if you have
emphysema, your body may react to the toxins and produce a special
kind of immune cell that is key in causing the lung damage. So perhaps if
doctors can find a way to change how this cell behaves, it might be
possible to reduce or limit the lung damage. Obviously, not smoking, or
stopping smoking, is the best way to prevent COPD or emphysema.
What Are the Problems with the Study? The study is quite small, which
means that the results may not be completely accurate; in particular, the
study did not include detailed information from patients who had never
smoked. So it is too soon to say for sure whether these special immune
cells really are the link between smoking and lung damage in
emphysema. Researchers will need to study many more patients with
emphysema as well as people who have never smoked.
Where Can I Find More Information? Two places to start are the
patient Web pages of the following professional organizations.
American Association for Respiratory Care: http://www.yourlunghealth.
org/diseases_conditions/copd/
The British Thoracic Society: http://www.brit-thoracic.org.uk/public_
content.asp?pageid=9&catid=21&subcatid=177
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